📌 X Insight Update[x_fin] (2026/06/24 23:35)

📈 Macro & Commodities

Oil is unwinding the war-risk premium as ships restart Strait of Hormuz crossings and US/Iran talks look less hostile. The harder read-through: gold and silver are getting hit because the market is repricing renewed rate-hike risk, not just de-escalation. 1
Sweden looks like the bigger unresolved housing bubble versus the US. Since 1996, home prices relative to incomes rose +156% by 2021 in Sweden versus +47% today in the US. The US cleared excess via the 2008 crash; Sweden only started deflating after 2022. 2

SPX 7800 by July OpEx is an aggressive melt-up target. The framing is not a base case with logic attached, but it is a clear upside call into options expiration. 3

$SOFI is showing relative strength: it stood out yesterday, gained +5% this morning, and is moving toward a retest of the breakout trigger. The tape is getting selective as AI/datacenter crowded trades weaken into key supports, so the next move is a major test for leadership. 4
SpaceX $SPCX likely marked a short-term top for the space trade. $ASTS is down nearly 50% in 4 weeks, while $RKLB is down over 40% after both ripped hard into the IPO. They are now back near major support, so the trade is shifting from chase mode to potential bounce-or-break setup. 5
$ASTS and $RKLB are being framed as needing to bottom immediately. The tone is joking, but the trade read is clear: today’s support reaction matters. 6

$QCOM spending $3.9B is a direct shot at $NVDA’s core moat: CUDA-style software lock-in. The bet is modular AI software that can run across anyone’s silicon. The market faded the move, with $QCOM down 2.7%, but the strategic message is that Qualcomm now has a moat story to pitch at Investor Day. 7
$MU reporting after the close is positioned as a market-wide catalyst, not just a single-name print. The read-through could hit semis, AI infrastructure, and memory-linked trades after hours. 8

AI healthcare is being framed as a massive theme, with biotech entering a potential AI-driven renaissance. The beneficiaries named are $ABCL, $RXRX, $TEM, and similar AI-bio names. 9

Lemonade reinsurance renewal terms could be a near-term catalyst in about a week. Based on prior CFO Tim Bixby commentary, the setup is for terms to stay the same or improve, with the cession rate at 20% or lower. Better model accuracy from more accumulated data is the core underwriting leverage point. 10

$BMNR is a cautionary bagholder case. The “keep stacking and HODL” call from January has turned into fresh new lows 6 months later, making the opportunity cost the real damage, not just the drawdown. 11

The INTC trade is structured as stock replacement, not a lotto ticket: buy the $50 strike, 2027/3 expiry deep ITM call with Delta near 1.0. If INTC is around $90–105 on 5/29, and later reaches $134, the deep ITM call should move almost like stock, implying about +$30–44 per share × 20,000 shares ≈ +$600k to $880k mark-to-market. 12